Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux
Vesicoureteral Reflux
About this trial
This is an interventional treatment trial for Vesicoureteral Reflux focused on measuring rare disease, renal and genitourinary disorders, vesicoureteral reflux
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Confirmed grade 3 or 4 reflux in at least one ureter by voiding cystourethrogram Breakthrough urinary tract infection despite standard antibiotic therapy OR Persistent reflux unlikely to resolve spontaneously Grade 3: 2 year reflux duration OR 1 breakthrough infection Grade 4: 1 year reflux duration OR 1 breakthrough infection Coexisting grade 1 or 2 reflux OR Resolved reflux (i.e., contralateral to the existing grade 3 or 4 refluxing ureter) allowed No reflux secondary to obstruction or neuropathic disease No gross urological abnormalities (e.g., megaureter requiring ureteral tapering or duplicity of ureters) --Prior/Concurrent Therapy-- Surgery: No prior surgery for correction of reflux No recent prior urological device implantation --Patient Characteristics-- Hematopoietic: No history of bleeding disorders Cardiovascular: No history of hypertension or cardiac disease Pulmonary: No history of pulmonary disease Other: No known allergies to contrast dyes, iodine, or shellfish No contraindications to general anesthesia No prior infections (other than UTIs) No immunodeficiencies No metabolic disease No social situation that would interfere with follow up Not pregnant Negative pregnancy test